期刊名称：CANCER IMMUNOLOGY IMMUNOTHERAPY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Aims and scope
Keeping readers informed of the latest research results in the fields of oncology and immunology has always been one of the main services provided by Cancer Immunology, Immunotherapy. To make this service even more comprehensive, the scope of the journal was expanded some years ago to include more of the progres being made in the various fields of biology concerned with biological response modifiers, thus enabling readers to keep up to date on the latest advances in our understanding of tumor-host interactions.
Tumor immunologists, clinical oncologists, virologists, and medical microbiologists involved in the development of methods of treatment and therapies for cancer patients will have access to the information contained in this journal. The journal publishes short editorials (including "position papers"), general reviews, original articles, and short communications, providing a forum for the most recent experimental and clinical advances in tumor immunology.
Manuscripts in triplicate should be sent to the appropriate Editor (see"Instructions for authors").
As to type of paper and manuscript preparation, see also "Instructions for authors"
Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.
Reports of animal experiments must state that the "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985) were followed, as well as specific national laws (e. g., the current version of the German Law on the Protection of Animals) where applicable.
The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfil the above-mentioned requirements.
This journal is included in the ADONIS service.
In the ADONIS service copies of individual articles can be printed out from compact discs (CD-ROM) on demand. An explanatory leaflet giving further details of the scheme is available from the publishers on request.
Instructions to Authors
Manuscript submission
Manuscript Submission
Permissions
Online Submission
Manuscript Submission
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities ?tacitly or explicitly ?at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.
Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Online Submission
Authors should submit their manuscripts online. Electronic submission substantially reduces the editorial processing and reviewing times and shortens overall publication times. Please follow the hyperlink “Submit online?on the right and upload all of your manuscript files following the instructions given on the screen.
Manuscript preparation
We urge authors to follow the guidelines for authors to speed up the review and publication process.
All manuscripts are subject to copyediting upon acceptance, however, authors are asked to ensure that manuscripts from non-native English language speakers should have the language and grammar checked by a native speaker or a professional agency. Poorly written articles cannot be reviewed and will be returned to the authors.
Authorship Criteria and Contributions
All listed authors should have seen and approved the final version of the manuscript.
All authors of accepted articles must sign an authorship form affirming that they have met all three of the following criteria for authorship, thereby accepting public responsibility for appropriate portions of the content:
1. substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
2. drafting the article or revising it critically for important intellectual content;
3. approval of the version to be published and all subsequent versions.
If authorship is attributed to a group (such as for multi-center trials), the group must designate one or more individuals as authors or members of a writing group who meet full authorship criteria and who accepts direct responsibility for the manuscript.
Other group members who are not authors should be listed in the Acknowledgment section of the manuscript as participating investigators.
Individuals who do not meet the criteria for authorship but who have made substantial, direct contributions to the work (e.g., purely technical help, writing assistance, general or financial or material support) should be acknowledged in the Acknowledgments section of the manuscript, with a brief description of their contributions. Authors should obtain written permission from anyone they wish to list in the Acknowledgments section.
Redundant, Duplicate or Fraudulent Publication
Authors must not simultaneously submit their manuscripts to another publication if that manuscript is under consideration by Cancer Immunology Immunotherapy.
Redundant or duplicate publication is a paper that overlaps substantially with one already published in print or electronic media. At the time of manuscript submission, authors must inform the editor about all submissions and previous publications that might be regarded as redundant or duplicate publication of the same or very similar work. Any such publication must be referred to and referenced in the new paper.
Copies of such material should be included with the submitted paper as a supplemental file.
Authors must not:
Willfully and knowingly submit false data
Submit data from source not the authors?own
Submit previously published material (with the exception of abstracts) without correct and proper citation
Omit reference to the works of other investigators which established a priority
Falsely certify that the submitted work is original
Use material previously published elsewhere without prior written approval of the copyright holder
Article types
Original Articles word limit ca. 4000 words, ca. 45 references, no more than six figures/tables excluding supplementary on-line only material.
Review Articles generally solicited by the editors but unsolicited proposals containing an abstract and outline can be sent to the editors for consideration.
Short Reports (called “Short Communications?word limit, 2000 words, 25 references, no more than two display items.
Case Reports generally not published by CII unless of outstanding interest from the immunological point of view.
Meeting reports CII is interested in the rapid publication of conference summaries. These should tell a scientific “story?and not be simply a list of speakers?statements. There is no formal limit to the length of meeting summaries but concise reports are highly desirable. These contributions will be peer-reviewed by two meeting attendees and by two others who did not attend the meeting. All cited speakers must have been given an opportunity to comment on and approve the draft before it is submitted. Conference organisers should please contact the appropriate editor in advance of their meeting.
Focused Research Review ?by invitation only - should be based on presentations made at conferences, primarily intended to review the author´s own work in a particular area. They should therefore not necessarily attempt a general overview of the field, but may provide only the background required for the "personal" review. They may also present opinions or hypotheses, but all submissions will be subject to the usual strict peer review process, and invitation to submit does not guarantee acceptance. They should start with an abstract, but the remainder of the paper can be structured as desired by the authors as long as the general CII "Instructions to Authors" are followed.
Articles will be published on-line in the order of acceptance, but the print version will bring together all those papers from a particular conference, together with a meeting report, if available. Articles should be of at least 2,000, at most 5,000 words, with ca. max. 50 references and 2 or 3 explanatory display items, preferably figures.
Focused Research Reviews may include original data, but previously published material must of course have copyright clearance. When submitting on-line, please note manuscript category as Focused Research Review and also which conference.
“Symposium-in-Writing?papers are from “virtual?symposia, not originating from a real conference, and consisting of a set of articles on a particular theme, each of which has been read and commented on by all contributing corresponding authors. Investigators who would like to organise a “Symposium-in-Writing?should contact the Editors for details.
Letter to the Editor ?CII occasionally accepts letters to the editor pertaining to articles published in the Journal. These should not exceed 1000 words and will be passed to the authors of the article to which the comment applies to solicit a response.
Instructions to Authors
0340-7004.pdf
Editorial Board
Editors in chief
Papers from North America and Japan to:
E. Mihich
Roswell Park Cancer Institute
Grace Cancer Drug Center
Elm and Carlton Streets
Buffalo, NY 14263, USA
Tel.: +1-716-845-8224
Fax: +1-716-845-4437
enrico.mihich@roswellpark.org
Papers from all geographical areas
except North America and Japan to:
G. Pawelec
Center for Medical Research (ZMF)
University of T黚ingen Medical School
Waldh鰎nlestrasse 22
72072 T黚ingen, Germany
Tel.: +49-7071-298 2805
Fax: +49-7071-888 4679
CII.pawelec@t-online.de
Editorial Board
A. Anichini, Milan
R.W. Baldwin, Nottingham
D. A. Berd, Philadelphia
R. Bolhuis, Rotterdam
O. Bruserud, Bergen
S. Canevari, Milan
W. Carson, Columbus
R. Choudhury, Stockholm
A. G. Dalgleish, London
W. Den Otter, Utrecht
C. Dosne de Pasqualini, Buenos Aires
M. J. Ehrke, Buffalo
F. Farzaneh, London
S. Ferrone, Buffalo
F. Garrido, Granada
M. J. Glennie, Southampton
J. W. Gratama, Rotterdam
P. Greenberg, Seattle
J. Greenman, Hull
P. Hersey, Newcastle(Australia)
E. Hersh, Tucson
F. Jotereau, Nantes
R. Kiessling, Stockholm
H. Kirchner, L黚eck
W. H. M. Kruit, Rotterdam
P. Livingston, New York
F. M. Marincolo, Bethesda
K. Matsushima, Tokyo
C. J. M. Melief, Leiden
M. Mellstedt, Stockholm
M. B. Mokyr, Chicago
J. J. Mule, Ann Arbor
S. Ostrang-Rosenberg, Baltimore
D. Pardoll, Baltimor
M. Pfreundschuh, Homburg/Saar
R. Rees, Nottingham
L. F. L. Reis, Sao Paulo
R. A. Reisfeld, La Jolla
N. P. Restifo, Bethesda
A. B. Rickinson, Birmingham
F. Sendo, Yamagata
E. Tahara, Hiroshima City
T. Taniguchi, Tokyo
S. Todryk, Dublin
A. Van Pel, Brussels
T. Whiteside, Pittsburgh
M. R. Young, Hines
| 
刊名字顺( Alphabetical List of Journals):
返回页首 